Frontiers in Oncology (May 2020)

Predicting Progression-Free Survival Using MRI-Based Radiomics for Patients With Nonmetastatic Nasopharyngeal Carcinoma

  • Hesong Shen,
  • Hesong Shen,
  • Yu Wang,
  • Yu Wang,
  • Daihong Liu,
  • Daihong Liu,
  • Rongfei Lv,
  • Yuanying Huang,
  • Chao Peng,
  • Shixi Jiang,
  • Ying Wang,
  • Yongpeng He,
  • Xiaosong Lan,
  • Hong Huang,
  • Jianqing Sun,
  • Jiuquan Zhang,
  • Jiuquan Zhang

DOI
https://doi.org/10.3389/fonc.2020.00618
Journal volume & issue
Vol. 10

Abstract

Read online

Objectives: This study aimed to explore the predictive value of MRI-based radiomic model for progression-free survival (PFS) in nonmetastatic nasopharyngeal carcinoma (NPC).Methods: A total of 327 nonmetastatic NPC patients [training cohort (n = 230) and validation cohort (n = 97)] were enrolled. The clinical and MRI data were collected. The least absolute shrinkage selection operator (LASSO) and recursive feature elimination (RFE) were used to select radiomic features. Five models [Model 1: clinical data, Model 2: overall stage, Model 3: radiomics, Model 4: radiomics + overall stage, Model 5: radiomics + overall stage + Epstein–Barr virus (EBV) DNA] were constructed. The prognostic performances of these models were evaluated by Harrell's concordance index (C-index). The Kaplan–Meier method was applied for the survival analysis.Results: Model 5 incorporating radiomics, overall stage, and EBV DNA yielded the highest C-indices for predicting PFS in comparison with Model 1, Model 2, Model 3, and Model 4 (training cohorts: 0.805 vs. 0.766 vs. 0.749 vs. 0.641 vs. 0.563, validation cohorts: 0.874 vs. 0.839 vs. 836 vs. 0.689 vs. 0.456). The survival curve showed that the high-risk group yielded a lower PFS than the low-risk group.Conclusions: The model incorporating radiomics, overall stage, and EBV DNA showed better performance for predicting PFS in nonmetastatic NPC patients.

Keywords